1. Home
  2. DNLI vs BUSE Comparison

DNLI vs BUSE Comparison

Compare DNLI & BUSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DNLI
  • BUSE
  • Stock Information
  • Founded
  • DNLI 2013
  • BUSE 1868
  • Country
  • DNLI United States
  • BUSE United States
  • Employees
  • DNLI N/A
  • BUSE N/A
  • Industry
  • DNLI Biotechnology: Biological Products (No Diagnostic Substances)
  • BUSE Major Banks
  • Sector
  • DNLI Health Care
  • BUSE Finance
  • Exchange
  • DNLI Nasdaq
  • BUSE Nasdaq
  • Market Cap
  • DNLI 2.1B
  • BUSE 2.0B
  • IPO Year
  • DNLI 2017
  • BUSE N/A
  • Fundamental
  • Price
  • DNLI $15.43
  • BUSE $24.68
  • Analyst Decision
  • DNLI Strong Buy
  • BUSE Buy
  • Analyst Count
  • DNLI 15
  • BUSE 7
  • Target Price
  • DNLI $33.62
  • BUSE $27.43
  • AVG Volume (30 Days)
  • DNLI 2.0M
  • BUSE 451.6K
  • Earning Date
  • DNLI 11-05-2025
  • BUSE 10-21-2025
  • Dividend Yield
  • DNLI N/A
  • BUSE 4.04%
  • EPS Growth
  • DNLI N/A
  • BUSE N/A
  • EPS
  • DNLI N/A
  • BUSE 1.13
  • Revenue
  • DNLI N/A
  • BUSE $498,525,000.00
  • Revenue This Year
  • DNLI N/A
  • BUSE $62.58
  • Revenue Next Year
  • DNLI $802.87
  • BUSE $11.62
  • P/E Ratio
  • DNLI N/A
  • BUSE $21.95
  • Revenue Growth
  • DNLI N/A
  • BUSE 16.77
  • 52 Week Low
  • DNLI $10.57
  • BUSE $18.40
  • 52 Week High
  • DNLI $33.33
  • BUSE $28.30
  • Technical
  • Relative Strength Index (RSI)
  • DNLI 56.61
  • BUSE 64.16
  • Support Level
  • DNLI $14.52
  • BUSE $24.12
  • Resistance Level
  • DNLI $16.20
  • BUSE $24.78
  • Average True Range (ATR)
  • DNLI 0.70
  • BUSE 0.49
  • MACD
  • DNLI -0.01
  • BUSE 0.11
  • Stochastic Oscillator
  • DNLI 62.44
  • BUSE 77.78

About DNLI Denali Therapeutics Inc.

Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.

About BUSE First Busey Corporation

First Busey Corporation is a financial holding company, whose subsidiaries provides retail and commercial banking services, remittance processing, and offers financial products and services with banking centers in Illinois, Missouri, Florida, and Indiana. The company's operations are managed through three operating segments consisting of Banking, FirsTech and Wealth Management. The banking segment generates a vast majority of its revenue.

Share on Social Networks: